Literature DB >> 1546120

Molecular properties of monoamine oxidases A and B.

S W Kwan1, J M Bergeron, C W Abell.   

Abstract

Monoamine oxidases A and B (MAO-A and B) catalyze the oxidative catabolism of biogenic amines and xenobiotics. Investigation of these mitochondrial membrane proteins shows that they differ in substrate preference, inhibitor specificity, tissue and neuronal cell distribution, immunological properties, and nucleotide and deduced amino acid sequences. Comparisons of MAO-A and B from the human, bovine, and rat species show strikingly high similarity (85-88%) in the amino acid sequences of each enzyme. Furthermore, three regions in MAO-A and B have sequence identities across species of 78, 88, and 86%. These regions correspond to a nucleotide-binding site near the N-terminal end that is found in the vast majority of enzymes that require flavin adenine dinucleotide (FAD), a region of unknown function, and the FAD-binding site toward the C-terminal end. Genomic clones of MAO-B which span almost the entire gene (greater than 40 kb) have been isolated, restriction mapped, and partially sequenced. Likewise, genomic clones of MAO-A that correspond to the 3'-flanking region have also been investigated. Current studies which focus on identification of the promoter and regulatory sequences should help to establish why MAO-A and B are localized in different subsets of neurons in brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546120     DOI: 10.1007/bf02246224

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes.

Authors:  P A Bond; R L Cundall
Journal:  Clin Chim Acta       Date:  1977-10-15       Impact factor: 3.786

2.  Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.

Authors:  M Da Prada; R Kettler; H H Keller; W P Burkard; D Muggli-Maniglio; W E Haefely
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

3.  The primary structure of bovine monoamine oxidase type A. Comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes.

Authors:  J F Powell; Y P Hsu; W Weyler; S A Chen; J Salach; K Andrikopoulos; J Mallet; X O Breakefield
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

4.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.

Authors:  A W Bach; N C Lan; D L Johnson; C W Abell; M E Bembenek; S W Kwan; P H Seeburg; J C Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Pentametric distribution of platelet monoamine oxidase activity.

Authors:  C R Cloninger; L von Knorring; L Oreland
Journal:  Psychiatry Res       Date:  1985-06       Impact factor: 3.222

6.  Monamine oxidase in schizophrenia and other behavioral disorders.

Authors:  D L Murphy; R Belmaker; R J Wyatt
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

7.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

8.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

9.  Assignment of genes for human monoamine oxidases A and B to the X chromosome.

Authors:  L M Kochersperger; E L Parker; M Siciliano; G J Darlington; R M Denney
Journal:  J Neurosci Res       Date:  1986       Impact factor: 4.164

10.  Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells.

Authors:  N C Lan; C H Chen; J C Shih
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

View more
  2 in total

Review 1.  Biochemistry and pharmacology of moclobemide, a prototype RIMA.

Authors:  W Haefely; W P Burkard; A M Cesura; R Kettler; H P Lorez; J R Martin; J G Richards; R Scherschlicht; M Da Prada
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Authors:  T R Norman; G D Burrows
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.